News About: Pharm. Industry
How listed pharmaceutical companies spent for R&D expenses?
In the 1st quarter of this year, KOSPI listed pharmaceutical companies have spent twice more into R&D than what KOSDAQ listed pharmaceutical companies spent.
Yakup Shinmoon(www.yakup.com) analyzed R&D expenses that 3...
Korean pharmas developed 9 products of 8 types biosimilars like Remsima
It was reported 9 biologic products of 8 types were developed by Korean pharmaceutical companies, such as Celltrion with the rheumatoid arthritis therapy ‘Remsima Inj.’
According to the Ministry of Food and Drug Safe...
Samsung Bioepis reveals clinical trial results of SB3 at ASCO in U.S.
Samsung Bioepis(CEO/President Han-Seung Ko) revealed the 1-year clinical trial result of SB3(Herceptin biosimilar, generic name: trastuzumab, European name: Ontruzant, Korean name: Samfenet), a breast cancer therapy.
...
Pharmaceutical Product Approval Renewal leads pharmas to reshuffle their products
The pharmaceutical product approval & registration renewal system starting last July was analyzed to lead the pharmaceutical industry to reshuffle their pharmaceutical products.
This is because 1 of 5 subjects to the...
How listed pharmas did with overseas sales and exports?
This 1st quarter, both of KOSPI and KOSDAQ listed pharmaceutical companies has a decrease in overseas sales & exports on average compared to the same quarter of the last year.
Yakup Shinmoon(www.yakup.com) analyzed o...
LG Chem targets Japan with ‘Etanercept’ referencing Enbrel
LG Chem will aggressively target the Japanese ‘Etanercept’ market worth of KRW 400 billion.
When it comes to this news on the 30th, LG Chem completed registering health insurance benefit price of ‘Etanercept BS, refe...
Hanall Biopharma & Daewoong Pharmaceutical announce U.S. Phase II clinical trial of new dry eye therapy
On the 29th, Hanall Biopharma and Daewoong Pharmaceutical announced their U.S. Phase II clinical trial(a.k.a. Topline) result of the dry eye treatment biosimilar HL036 that they are jointly developing. The Phase II cl...
Chong Kun Dang signs co-sales agreement of dementia therapy ‘Aricept’ with Eisai Korea
Chong Kun Dang(CEO Young-Joo Kim) signed a co-sales agreement of dementia therapies ‘Aricept’ and ‘Aricept Evess’ with Eisai Korea at the Chong Kun Dang’s headquarters located in Chungjeongno, Seoul on the 28th.
Unde...
How listed pharmas did with sales?
In the 1st quarter of this year, both KOSPI and KOSDAQ listed pharmaceutical companies had an increase of approximately 6% in sales compared to the same quarter of the last year.
Yakup Shinmoon(www.yakup.com) analyze...
Shin Poong Pharm to present innovative stroke drug ‘SP-8203’ at BIO USA
Shin Poong Pharm(CEO Jae-Man Yoo) will participate in ‘2018 BIO International Convention,’ the world’s largest biopharmaceutical convention held in Boston between 4 and 7 June, and will announce clinical results about...
